Kangshino Shanghai MRNA Industrialization Base has a localization rate of 80%

First Financial News on August 18, vaccine manufacturer Kangxino Biological Co., Ltd., a new MRNA vaccine industrialization base in Lingang, Shanghai, will be completed at the end of this year. The first phase of planning capacity is 100 million preparations, and the number of production will increase to 200 million later. Raw fluid. Liu Jian, general manager of Kangshino Biological Shanghai Company, told reporters at an industry conference on nucleic acid drugs: "Kangshino's MRNA platform construction has been basically completed, verifying the feasibility of production technology. Once the vaccine is approved in the future, it will quickly realize it will be realized Industrialization. Shanghai Lingang Base will also become the main industrialized base of the Kangshino MRNA platform. "

According to smart bud data, Kangsino Biological Co., Ltd. and its affiliated companies have applied for a total of nearly 100 patents, of which more than 80 invention patents. The company has a patented technology layout in China, the United States, Europe, Canada and other countries. By further analyzing its patented technology data, the company's patented technology is mainly deployed in the fields of adenovirus, fusion protein, polysaccharides, pneumoniac bacteria and other fields.

According to public information, Kangshino Biological Co., Ltd. registered in Tianjin Binhai New District in 2009. It is a national high -tech enterprise founded by the executive team of multinational pharmaceutical companies. In March 2019, Kangsino Bio was listed on the main board of the Hong Kong Stock Exchange. On August 13, 2020, Kangshino Bio officially landed on the science and technology board, becoming the first "A+H" vaccine stocks since the opening of the science and technology innovation board. Essence

The R & D team of Kangxino Bio has gathered a number of large -scale pharmaceutical companies such as Sanofibat, Astrachian, and Wyeth (now Pfizer), and leads well -known scientists and senior experts in the vaccine industry to establish an international vaccine. Five core technology platforms such as virus carrier technology, synthetic vaccine technology, protein structure design and reorganization technology, MRNA technology and preparation technology, and drug supply technology have a number of core intellectual property rights and proprietary technologies of vaccine. The 17 types of innovative vaccine products have covered a series of diseases such as new types of coronary virus pneumonia, Ebola virus disease, tuberculosis, meningitis, Baibai, and shingles.

- END -